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An Economic Evaluation of Finding 
Cases of Hepatitis B and C Infection in 
UK Migrant Populations 
1 Foreword 
The work contained in this document has been commissioned by the National 
Institute for Health and Clinical Excellence’s (NICE) Public Health programme.  It 
represents part of a wide body of work aimed at assessing the effectiveness and 
cost-effectiveness of methods ‘to promote and offer testing to people at risk of 
hepatitis B / C infection’.  This section reports economic evaluations of case finding 
interventions for hepatitis B / C infection in people who are migrants to the UK.  Two 
separate models are reported, one relating to testing for hepatitis B (HBV) infection 
and the other for hepatitis C (HCV) infection; the cost-effectiveness of 
simultaneously testing for both infections is not modelled at any point.  A model 
relating to interventions for intravenous drug users (IDUs) is available in a separate 
report. 
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2 Executive summary 
2.1 Objectives 
The specific aim of this report was to assess the cost-effectiveness of interventions 
to increase hepatitis C (HCV)/hepatitis B (HBV) testing and/or treatment uptake in 
migrant populations to the UK.  However, the accompanying systematic review and 
call for evidence produced few useful studies on intervention effectiveness on which 
to base the cost-effectiveness modelling.  Therefore, with the agreement of the PDG, 
particular efforts were made to also highlight the parameters/areas of greatest 
uncertainty in terms of determining cost-effectiveness, in order to inform the further 
research recommendations. 
2.2 Methods 
To achieve these objectives, two decision models were built one relating to HCV 
testing and treatment, the other to HBV.  Both models evaluated the cost-
effectiveness of a hypothetical ‘one off’ intervention aimed at increasing testing, 
although it is loosely based on a recent UK study available as a conference 
abstract1.  The comparator intervention consisted of a background rate of testing 
only (i.e. no intervention).  The majority of evidence required to populate the model 
was taken from UK health technology assessment (HTA) reports, Health Protection 
Agency (HPA) publications and the IDU model also commissioned as part of this 
project.  Both case finding models used a Markov approach, cycled 6 monthly and 
were analysed using cohort techniques.  Uncertainty was assessed using 
probabilistic- and one way-sensitivity analysis.  Analysis of covariance (ANCOVA) 
was also undertaken.  Health outcomes were expressed in terms of Quality-Adjusted 
Life-Years (QALYs).  Costs were assessed from a UK National Health Services 
(NHS) perspective and expressed in £2010/11 prices.  
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2.3 Results 
The results from the HCV/HBV models produced estimated incremental cost-
effectiveness ratios (ICERs) of approximately £10,200 and £20,900 per additional 
QALY respectively, when the assumptions were made that the HCV/HBV prevalence 
was 2%, the mean cost of the intervention was £20 per person invited for a test and 
a 17.5% chance of testing for a period of 6 months as a result of the intervention.  
The one way sensitivity analysis and ANCOVA suggested that both model results 
were highly sensitive to a number of parameters including the rate at which future 
QALYs are discounted, the infection prevalence, assumptions regarding treatment 
uptake, the costs and effectiveness of the intervention.  The results from the HBV 
model were also particularly sensitive to assumptions regarding the proportion of 
tested individuals who required treatment and the likelihood of household contacts 
requiring treatment for CHB. 
2.4 Summary 
The results from these analyses suggest that HCV case finding is likely to be cost-
effective at a 2% prevalence level and at a willingness to pay per additional QALY of 
£20,000 if it increases testing to 17% and costs £50-75 per person tested.  This 
conclusion was robust to most alternative assumptions except those related to 
treatment uptake.  The base case ICER for HBV case finding at the same 2% 
prevalence level, intervention effect and cost was about £21,000. Thus it is on the 
cusp of the £20,000 per additional QALY cost-effectiveness threshold.  However, this 
result is highly sensitive to a number of assumptions, particularly those relating to 
treatment uptake, contact tracing and the proportion of identified cases that require 
treatment.  Thus, there is a large amount of uncertainty around the base case ICER. 
All are areas where evidence is lacking, and further research is required if more 
robust estimates of cost-effectiveness are to be produced in the future. 
7 
 
2.5 Suggested areas for further research 
Research on the following would particularly help to produce more robust estimates 
of cost-effectiveness in the future: 
 Intervention effectiveness 
 Intervention costs 
 The likelihood that identified cases of HBV require treatment 
 The effectiveness of case finding 
 The prevalence of both HBV and HCV infections, but particularly HBV 
 Treatment uptake rates 
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3 Project scope 
The project scoping (briefing) document was clear that the interventions to be 
evaluated should focus on identifying cases of HBV / HCV in migrant populations to 
the UK and / or encouraging uptake of treatment.  The original intention was to use 
the results from the systematic review by Liverpool John Moores University (LJMU)2 
and information available via PDG members, and a later call for evidence, to define a 
set of interventions to evaluate.  However, very few studies assessing intervention 
effectiveness were identified meaning that producing robust estimates of cost-
effectiveness would be difficult.  Therefore, in the absence of this evidence, the 
decision was made by the PDG to also focus the cost-effectiveness analyses on 
establishing potential research priorities from an economic perspective.  That is, to 
undertake the evaluation but also to identify the parameters that are particularly 
important in determining the cost-effectiveness of case finding as well as highlighting 
those that are not. 
4 Literature review 
The systematic literature search undertaken by LJMU2 for this NICE Public Health 
Project suggests that a only small number of economic evaluations relating to the 
identification of cases of HBV/HCV infections in migrants to the UK have been 
published to date.  Perhaps the strongest from a methodological stance is the study 
by Veldhuijzen et al 3.  However, the main criticism of this study from a policy 
perspective is that the impact of increased testing was based on participation rates in 
breast cancer screening studies, presumably because of a lack of basic evidence on 
intervention effect.  A more detailed critique of the Veldhuijzen study is provided in 
the LJMU2 report. No additional reviewing has been attempted here but it and other 
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studies have been used as a source of evidence to estimate a number of the model 
parameters and to inform their design. 
5 A prerequisite to establishing the cost-effectiveness of case finding 
By definition, for HBV/HCV case finding to be cost-effective, it is essential that 
subsequent treatment also represents value for money.  This is because the overall 
incremental cost per Quality-Adjusted Life-Year (QALY) equals the sum of case 
finding, testing and the cost of treating, all divided by the number of QALYs gained.  
Since no QALYs are gained from finding and testing without treatment, then the 
overall cost per QALY will be greater than the cost per QALY for treatment. If the 
cost per QALY for treatment is higher than the threshold at which an intervention is 
deemed cost-effective, then the overall cost per QALY (which is higher again) will 
exceed the cost effectiveness threshold. 
A brief examination of NICE-related 4-6 and other relevant literature 7, 8 suggests that 
most if not all reported ICERs of recommended HBV/HCV treatments are below a 
cost-effectiveness threshold value of £20,000; indeed they were often substantially 
less than this.  Thus this basic prerequisite for case finding to be cost-effective has 
been fulfilled. 
6 Methods 
6.1 General Framework 
Two de novo economic decision models were built to assess the objectives, one for 
increasing the likelihood of finding cases of HBV and the other for finding cases of 
HCV infection, both in migrant populations to the UK. No attempt has been made to 
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assess the cost-effectiveness of finding HCV and HBV in a single model, because of 
the complexities involved of modelling co-infection. 
Both models are based on discrete-time (Markov) approaches.  Discrete-time 
models are convenient/appropriate to use when it is important to consider the costs 
and benefits of treatment options over relatively long periods of time, as is the case 
with the natural history of both HBV and HCV infection 9-12.  In all instances, the 
models were evaluated using 1,000 probabilistic sensitivity analysis (PSA) runs. 
Analysis of covariance analyses (ANCOVA) and a number of one way sensitivity 
analyses have also been reported, in order to highlight the parameters that were 
most important in terms of driving the results.  The models were built using TreeAge 
Pro 2009 and 201113, whereas the ANCOVA was undertaken using STATA version 
1214. 
A model structure was created to represent HBV disease progression and current 
understanding of policies regarding disease management, using PDG members to 
provide necessary clinical advice where necessary.  The natural history element of 
the model was based on Shepherd et al. 5, 7.  The majority of model parameters were 
estimated using previous HTA reports 4, 5, 7, 15, Health Protection Agency (HPA) 
publications 16, 17, data provided on request by the HPA and other literature sources.  
Where necessary data were missing, assumptions were made also using expert 
opinion where possible.  It was assumed that infection transmission could not occur 
in either model, as it is understood that the majority of infections that happen in these 
populations occur outside of the UK.  
The HCV model structure is very similar to the HCV IDU18 analysis that was also 
constructed for this NICE Public Health project. The main changes relate to the 
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parameter estimates, such as intervention effects and treatment uptake, and that the 
migration models do not consider infection transmission.  The latter was assumed 
because it is believed that relatively few infections occur in the UK as a result of 
transmission within the country, with around 90% of HBV infections being acquired 
outside of the UK.  
All costs are displayed in £ using 2010/11 prices.  Where necessary, costs were 
inflated using the Hospital and Community Health Services Index19.  Both models 
cycled 6-monthly, used a lifetime horizon and were carried out from a UK National 
Health Service (NHS) cost perspective.  Outcomes were expressed in terms of 
QALYs and all future base case costs. QALYs and costs were discounted at 3.5% 
per annum according to current NICE recommendations20. 
6.2 The Decision Problem 
Given the paucity of effectiveness evidence, the decision was made to evaluate a 
hypothetical intervention for both HCV and HBV models, although it is broadly based 
on the ‘opt out’ case finding approach described in a recent conference abstract by 
Lewis et al 1.  In this study, Pakistani/British Pakistani people registered at GPs were 
written to and invited to opt out of HCV/HBV case finding.  Those who did not opt out 
were telephoned and asked to attend testing clinics. 
The basic logic underlying each model was that increased testing leads to an 
increase in the number of people who are diagnosed with chronic HBV/HCV and 
treated and/or reduces the time it takes for a person to start treatment.  Each model 
run was assumed to include a cohort of individuals who were all eligible for HCV or 
HBV testing, a proportion of whom were infected.  The ‘intervention’ was designed to 
increase the likelihood of testing for each infection, over the initial model cycle 
(6 months).  After this time, the intervention effect was assumed to be zero, with the 
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probability of testing reverting to background levels.  The comparator technology was 
defined as the background chance of testing; i.e. a ‘no intervention’ option. 
6.3 Model Structures and how they work 
6.3.1 The HBV model 
The HBV model is much more detailed than its HCV counterpart, largely because of 
greater complexities in terms of modelling the disease progression process, but also 
because it includes contact tracing.  The model starts by creating a cohort of ‘index’ 
cases, a proportion of whom are HBsAg+ according to the prevalence parameter.  
Known HBsAg- individuals remained in the model with a general population level of 
mortality but incurring no further HBV-related costs.  On the other hand, known 
HBsAg+ people were assumed to undergo a full viral profile to establish their 
infection stage and suitability for treatment.  Individuals with known acute infection 
were assumed to be offered a repeat test in 6 months time (i.e. the next model 
cycle).  Whether infection status was known or unknown, individuals with acute 
infection either cleared the infection in the following cycle or developed chronic 
hepatitis B (CHB).  All individuals with known CHB were offered treatment or 
monitoring strategies, depending on their stage of infection, alanine transaminase 
(ALT) and HBV RNA levels, broadly according to recent European Association for 
the Study for the Liver (EASL) guidelines (Figure 1)21.  Mutually exclusive stages of 
CHB that were modelled included: HBeAg seroconverted (where ALT levels and 
HBV RNA are both low), hepatitis B e antigen negative (HBeAg-) and hepatitis B e 
antigen positive (HBeAg+) disease.  The infection status of all individuals with CHB 
was assumed to become known if/as soon as they developed decompensated 
cirrhosis (DC), hepatocellular carcinoma (HCC) or required a liver transplant (Figure 
2). 
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Individuals with CHB whose infection status was unknown and individuals that tested 
HBsAg+, but who declined or were not offered treatment, were assumed to develop 
progressive disease according to a set of defined transition probabilities (Table 2).  A 
different set of transition probabilities was used to define CHB disease progression 
for those who accepted treatment (Table 2). 
Current UK NHS HBV-testing policy is to contact household members once a case 
has been identified.  This possibility was therefore included in the model by 
assuming that each index case who was HBsAg+ (whether known or unknown) was 
associated with a household of individuals and that a proportion of these people had 
CHB at the start of the model (Table 2).  Contacts that were indentified and tested 
HBsAg+ were assumed to be managed as per index cases, and were assumed to be 
‘known’ if they developed symptoms related to CHB such as decompensated 
cirrhosis.  
Efforts were made via the HPA to gather evidence on the size of households, the 
probability that contacts were HBsAg+ and the likelihood that contacts could be 
traced in the first instance.  However, this proved difficult as the information was not 
routinely recorded and most infections often did not appear to relate to the 
populations of interest (i.e. migrant populations).  Instead, the mean household size 
was estimated using evidence from the Office for National Statistics along with an 
assumed discrete distribution and probability of infection (Table 1 and Table 2).  
Household contacts of HBsAg- index cases were not modelled, as they would not be 
traced, meaning by definition their inclusion or exclusion from the analysis cannot 
affect the incremental results. 
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6.3.2 The HCV model 
The structure of the HCV model is very similar to the model built for the IDU cost-
effectiveness analysis18 (Figure 2).  It is also similar to other cost-effectiveness 
models that have incorporated HCV disease progression 4, 15).  It consists of nine 
main health states: HCV negative (uninfected), mild disease, moderate disease, 
compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocelluar 
carcinoma (HCC), liver transplant, post liver transplant and dead.  The first four of 
these health states were further subdivided into whether or not individuals: 1) were 
undiagnosed, 2) have been diagnosed, 3) were receiving treatment, 4) had 
responded to treatment (sustained virological response [SVR]), 5) had failed 
treatment or 6) had not been referred or declined treatment.  As per the HBV model, 
in each cycle, individuals could be tested for HCV, according to the intervention 
effects and the background rate of testing.  Individuals who tested positive would be 
offered treatment at a given rate.  Individuals who accepted treatment received it for 
6 months at which time they were considered to be SVRs or not.  Individuals who 
tested HCV-antibody-negative were assumed to incur no further costs.  Individuals 
with SVR were assumed to have utility levels above those related to non-SVRs and 
a general population level of mortality and not to experience any further disease 
progression.  As with the HBV model, those who were not tested were assumed to 
have ‘known’ infection only if and when they developed decompensated cirrhosis or 
hepatocellular carcinoma. 
Neither model includes possible adverse events associated with anti-HBV or anti-
HCV treatments, treatment resistance or the possibility of treatment switching. 
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6.4 Test accuracy 
In all simulation runs, the diagnostic tests were assumed to be 100% accurate.  
However, it should be noted that all individuals who tested HBsAg+ received a full 
viral profile before treatment, meaning that individuals who are genuinely HBsAg- are 
unlikely to mistakenly receive treatment. 
6.5 Infection prevalence 
The proportion of people with a given infection/disease is an important consideration 
within any economic evaluation that assesses the cost-effectiveness of case finding 
interventions.  Data are available from the HPA on the number of people who are 
tested for HCV and HBV each year in specific UK surveillance sites (thought to cover 
about 30% of the population), although there appears to be some question as to how 
well it approximates ‘true’ underlying levels of HBV infection.  The data are also 
broken down by a number of ethnic groupings, the most useful in the context of this 
report being South Asians (HBV/HCV prevalence of approximately 2% each).  
However, evidence suggests that the infection prevalence varies by 
migrant/community group.  For example, the prevalence of CHB in UK Chinese 
migrants is thought to be between 7%22, 23 and 20% (Personal communication Eddie 
Chan), implying that there is a large degree of heterogeneity within and across 
communities.  Thus, rather than sampling the infection prevalence for each model 
run, it was fixed in an attempt to mimic intervention costs and effects in specific 
communities.  In the base case, the prevalence was fixed at 2% for both HCV and 
HBV infection but increased to 5% (as an assumed upper limit) and 20% in the one 
way sensitivity analyses respectively. 
6.6 Cohort demographics 
HPA data suggests that the average age at HBV/HCV diagnosis in South Asian 
populations is approximately 35 years of age16.  Although this was used as the 
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starting age in the model, it is an imprecise estimate of the age at diagnosis when 
used in the context of this modelling exercise (as individuals enter the model at this 
age, but not all will be tested immediately).  For this reason, the age at entry to the 
model was varied in the sensitivity analysis.  For the sake of simplicity the same age 
was assumed for all household contacts in the HBV model. 
Evidence available from the HPA also suggests that migrant people with HCV are 
one third as likely to be infected with genotype 1 as with genotype 2/3.  As treatment 
response is affected by genotype, this evidence was included in the model.  
However, the sample size for this evidence was not available, meaning that the 
distribution had to be assumed (Table 2).  
Neither models distinguished between males and females, or make any attempt to 
differentiate between first- or later-generation migrants either in terms of 
demographics or testing/treatment behaviour.  Moreover, all migration was assumed 
to be permanent insofar as the NHS was liable for all costs and consequences 
associated with HBV/HCV infection. 
6.7 The background probability of testing 
Primary cases infected with HBV/HCV were assumed to be identified either as the 
result of the intervention, because they developed symptoms related to chronic 
hepatitis (decompensated cirrhosis or hepatocellular carcinoma) or because of a 
‘background’ probability of testing, which was estimated as follows.  First, the total 
population of the UK is estimated to be 62.3 million of which 3.2% are estimated to 
be of South Asian origin.  Second, HPA data suggests that in 2010 17,226 HBV tests 
were undertaken in the UK in South Asian people, excluding all ante-natal tests; data 
thought to cover about a third of all tests.  Thus, the annual background probability of 
testing was estimated to be ([[1/0.333]*17,226]/[62.3 million*0.032]) = 2.6%.  This 
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probability was used in both HBV and HCV models, although it was varied using one 
way sensitivity analysis. 
6.8 Intervention effects and treatment uptake 
The base case rate of testing in the first 6 months in the intervention arm (i. e. the 
intervention effect) was broadly based on the abstract by Lewis et al, for the 
described opt out option.  In this study approximately 20% (223/1,134) of individuals 
invited for a HBsAg test received it.  However, this estimate was not directly 
incorporated into the evaluation using a beta distribution, as is traditionally the case 
for the following reasons.  First, the sample size was large, so very little uncertainty 
was generated when the corresponding beta distribution was sampled.  Given one of 
the project aims was to assess the potential importance of each parameter in terms 
of determining cost-effectiveness, this wasn’t considered to be helpful.  Second, 
there are other issues with the design of the study which would suggest that the 
(relative) treatment effects are more uncertain than they might appear at face value.  
For example, the study was not randomised or controlled.  Lastly, other 
interventions, including two also reported by Lewis et al1, were much less successful 
in terms of the numbers of people who were tested.  For these reasons, the 
assumption was made to specify the intervention effect as a uniform distribution with 
a mean (probability) of testing in the initial 6 month intervention period of 0.175 
U~(minimum 0.05, maximum 0.3).  In other words, in the base case it was assumed 
that the intervention effect led to an average of 17.5% of targeted individuals being 
tested within the initial 6 months.  After this time, the intervention effect was 
assumed to be zero, but with a remaining background level of testing. 
No useful quantitative evidence could be found on the probability of treatment uptake 
specifically in migrant populations, following a positive diagnosis for HCV or HBV.  
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Moreover following conversations with experts, it remained very unclear whether the 
value was indeed likely to be ‘high’ or ‘low’, although there was some suggestion that 
it might vary by community.  The assumption of 80% uptake per 6 months was used 
in the base case. In addition to being sampled in the PSA, both the intervention 
effects and treatment uptakes were subject to further one way sensitivity analysis. 
6.9 Utilities and costs 
Utility values are combined with estimates of survival in order to calculate QALYs.  
All utility values for the HBV model were sourced from a recent HTA monograph by 
Shepherd et al5, including age specific adjustments (Table 3), as were most of the 
required costs (Table 4).  The initial test for HBV infection was a surface antigen test 
(HBsAg), costing £10 per test.  Clinical advice suggested that when treatment is 
indicated for HBsAg+ people, it typically consists of pegylated interferon for 
12 months, or entecavir or tenofovir for a minimum of 3-5 years but of an unknown 
maximum duration.  Rather than evaluate the cost-effectiveness of each treatment 
option, the base case assumed that all individuals who required and accepted 
treatment received either entecavir or tenofovir until they achieved low ALT and HBV 
RNA levels (or HBeAg serocoverted).  For the HCV model, individuals were 
assumed to be initially tested for hepatitis C antibodies costing £10 with a 
confirmatory PCR test costing £70. 
The utility values (other than the intervention cost) used for the remaining HCV 
model parameters were the same as those used in the IDU cost-effectiveness 
analysis (see Tables 1 and 2 in the IDU report18).  The costs associated with 
compensated cirrhosis, decompensated cirrhosis, hepatocelluar carcinoma, liver 
transplantation and post-liver transplantation were the same as those used for the 
HBV model5, in order to be consistent with it. Other remaining costs, such as those 
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associated with the mild-SVR, moderate-SVR and compensated cirrhosis-SVR 
health states, were broadly the same as those used in the IDU analysis. 
No useful quantitative evidence could be found on the likely cost of providing an 
intervention for HBV or HCV case finding.  Therefore, the assumption was made in 
the base case that it cost £20 per person eligible for a test (excluding household 
contacts in the HBV model), with a standard error of a third of this amount.  
Therefore, if each model run had contained 100 people, the total mean intervention 
cost would have been £2,000.  Despite this assumption, it is acknowledged that ‘true’ 
intervention costs are likely to vary widely according to intervention design.  For 
example, a one-off sweep of GP records to indentify people to invite for testing, if 
possible electronically, might have far lower upfront costs than interventions to 
increase ‘awareness and testing’ amongst relevant health care professionals; even if 
the latter has a longer duration of effect. 
6.10 Transition probabilities 
6.10.1 Initial probabilities 
Initial probabilities are required in discrete time models, as they indicate where 
individuals enter it. For the HBV model, individuals were either HBsAg- or HBsAg+, 
although all were assumed to be unaware of their infection status.  Data from the 
HPA, both published 16 and via personal communication, were then used to 
subdivide infected individuals by stage of disease (Table 2).  For the HCV model, the 
initial distributions were based on the values calculated by calibration techniques for 
the IDU model. 
20 
 
6.10.2 All cause mortality 
Individuals without HCV / HBV infection, those who cleared acute HBV infection and 
HCV individuals with a sustained virological response were assumed to have a life 
expectancy equivalent to that of the general UK population 24. 
6.10.3 Disease progression and treatment effects 
The majority of the information required to parameterise the HBV disease 
progression model was taken from Shepherd et al5, with two notable exceptions.  
First, in Shepherd et al, the parameters were specified as beta distributions, with 
calculated residuals, so that PSA could be undertaken.  In this analysis however, the 
way the HBV model was built meant that multivariate alternatives to beta 
distributions were required, namely Dirichlet distributions, to prevent sampling 
probability values that sum to greater than one12.  To do this, the mean values 
presented by Shepherd were converted to Dirichlet distributions by assuming a 
sample size of 200; taken to represent a reasonably sized RCT.  For example, if 
Shepherd et al. specified mean beta distributed values of 0.2, 0.3 and 0.5 (1-0.2-
0.3), then the corresponding Dirichlet distribution was calculated to be α(40,60,100).  
Second, newer drugs have been recommended by NICE for the treatment of HBV 
since the Shepherd monograph was published, specifically entecavir and tenofovir.  
Similarly to Shepherd et al5, treatment effects for people in the HBV model for 
HBeAg+ and HBeAg- individuals were specified as the probability of HBeAg 
seroconversion and normalisation of ALT levels respectively.  The absolute 
treatment effects (or probabilities of response) were both taken from a recent 
systematic review and meta-analysis by Woo et al25, which at 1-year, were 23% and 
73% respectively. The same disease progression parameters, treatment effects and 
distributions specified for the HCV IDU model were used in this migrant version. 
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7 Results 
7.1 HCV 
The base case incremental cost-effectiveness ratios (ICERs) assuming prevalence’s 
of 2% and 5%, were estimated to be £10,200 and £7,500 respectively (Table 5).  
The cost-effectiveness acceptability frontiers (CEAFs) suggested that the uncertainty 
around the intervention being the most cost-effective option was low in both 
prevalence settings, at a willingness to pay for an additional QALY of between 
£20,000-30,000 (Figure 3 and Figure 4).  However, results from the one-way 
sensitivity analysis (Table 6) showed that the ICERs were sensitive to assumptions 
regarding the probability of treatment uptake, the analysis time horizon and 
particularly the cost and effectiveness of the intervention.  The ANCOVA results 
support this finding, as it clearly shows that most of the uncertainty in the incremental 
costs and QALYs was explained by the intervention effect and the intervention cost 
(Figure 6). 
7.2 HBV 
The results from the analysis estimated that the intervention cost an additional 
£20,900 and £12,200 per additional QALY at prevalences of 2% and 20% 
respectively compared with ‘no intervention’ (Table 7 and Figure 7).  However, 
similar to the HCV results, the base case ICER was particularly sensitive to 
assumptions regarding the treatment effect and cost.  It was also particularly 
sensitive to assumptions regarding the prevalence, the likelihood of requiring 
treatment when identified, assumptions regarding contact tracing, the rate at which 
future QALYs are discounted and the time horizon (Table 8) 
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8 Summary 
Two economic evaluations of a hypothetical case finding intervention in migrant 
populations to the UK have been presented in this report, one relating to cases of 
HBV, the other to HCV.  The results suggest that a ‘one-off’ HCV case finding 
intervention in prevalence areas of 2% or more, that achieves levels of testing of at 
least 17.5%, is likely to be cost effective at a willingness to pay for an additional 
QALY of £20,000 if it costs between £50-75 per person invited for a test.  This 
finding was generally robust to alternative assumptions, except those relating to 
treatment uptake.  For example, if it was assumed that only 25% of indentified HCV 
cases ever take up treatment, then the ICER increased to well over £30,000 per 
additional QALY.  
The base case ICER for HBV case finding was estimated to be approximately 
£21,000 when similar assumptions were made (intervention effect of 17.5%, £20 per 
person invited for a test and a 2% prevalence level).  Thus it is on the cusp of the 
£20,000 per additional QALY cost-effectiveness threshold.  However, it is important 
to note that this base case result was highly sensitive to a number of assumptions, 
including the prevalence, treatment uptake rate, the effectiveness of contact tracing 
and the proportion of identified HBsAg+ individuals who required treatment.  Indeed, 
the latter point almost exclusively explains the difference in the HBV and HCV case 
finding results - based on HPA data, the base case assumed that only 20% of 
identified CHB cases required treatment.  No such consideration is included in the 
HCV model, where all identified cases are considered eligible for treatment.  
However, the HBV case finding ICER decreased to approximately £12,000 per 
additional QALY if the prevalence was assumed to be 20%, which is thought to be 
representative of the infection prevalence in some UK-Chinese communities. 
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Irrespective of the results and whether or not they are above or below a threshold 
QALY value, it should be noted that the supporting systematic review2 reported a 
very limited amount of effectiveness evidence on case finding interventions and that 
our base case testing up take rate of 17.5% over 6 months was based on a single 
intervention reported in a recent conference abstract1.  Indeed, the effectiveness of 
two other interventions reported in the same abstract were much lower than 17.5%.  
Similarly, no useful evidence could be found on the costs of delivering case finding 
interventions in the target groups of interest.  These considerations are important as 
the sensitivity analysis clearly indicates the reliance of the ICER on the intervention 
costs and effects. 
In addition to the intervention costs and effects, the sensitivity analysis showed that 
the models’ results were dependent on assumptions regarding treatment uptake (for 
which there is very little evidence in migrant populations), the prevalence, the time 
horizon and the rate at which future QALYs are discounted.  For the HBV model, the 
assumptions regarding the likelihood of finding further cases of infection via 
household contact tracing was also particularly important.  Thus, the scope and 
importance of further research in these areas is likely to be considerable. 
The base case 2% HBV prevalence results is higher than the incremental cost per 
QALY of €8,966 reported by Veldhuijzen et al 3.  However, possible reasons for the 
difference include their use of a HBsAg+ prevalence nearer 3.5%.  Further 
comparison between with this study is difficult not least because the evaluation by 
Veldhuijzen appears to be assessing the cost-effectiveness of more than one 
intervention, increasing the likelihood of testing and subsequent referral to a 
specialist physician, but the (combined) intervention effects are unclear. 
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Both the HBV and HCV decision models contain a number of limitations.  First, the 
cost-effectiveness of simultaneously testing for HBV and HCV was not considered 
because of the difficulties of modelling co-infection.  While at some level it would 
appear intuitive to believe that simultaneously testing could only increase cost-
effectiveness, this rests on the assumption that prevalence rates are similar, or are 
at least positively correlated in a given community.  For example, HBV prevalence 
rates of 20% in UK Chinese communities have been recorded, but it appears that 
HCV is much less of a concern in these communities.  Thus, testing for HCV in UK 
Chinese communities might not make economic sense in the first instance.  
However, for UK Bangladeshi / Pakistani communities, HBV and HCV prevalence’s 
of around 1 to 2% have been recorded thus, if active case finding does happen, it 
would make sense to test for both infections simultaneously. 
The approach taken to modelling treatment uptake was a particular limitation.  In the 
models it was assumed that there was a recurring probability of receiving treatment, 
and in this sense, the parameter reflected a time to treatment rather than a 
probability of ever accepting treatment.  This approach was taken as it was simple to 
implement in the model, and a lack of detailed relevant evidence meant that more 
sophisticated attempts were unwarranted.  While the results from the ANCOVA 
suggested that treatment uptake was not a particular issue in terms of driving the 
cost-effectiveness results, further investigations involving structural changes to the 
HCV model suggested that different assumptions lead to very different results, and 
that it is indeed an important area in terms of future research. 
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9 Suggested areas for further research 
Research on the following would particularly help to provide more robust estimates 
of cost-effectiveness in the future: 
 Intervention effects 
 Intervention costs 
 The likelihood that identified cases of HBV require treatment 
 The relative effectiveness of case finding 
 The prevalence of both infections, but particularly HBV 
 Treatment uptake rates 
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11 Tables 
 
Table 1: Household size 
Size of household Probability 
0 0.10 
1 0.13 
2 0.18 
3 0.22 
4 0.18 
5 0.19 
The mean household size of 2.82 was taken from Office for National Statistics information, but the discrete distribution 
was assumed 
 
Table 2: HBV probability parameters, initial- and other-distributions. 
Parameter Mean value PSA parameter^ Source 
Intervention effect*for 6 months 0.175 Uniform, (0.05;0.3) Lewis 
1
 and assumption 
Annual background rate of testing** 0.026 Beta, n = 1993600, r = 52200 HPA 
16
 and assumptions 
Referral / treatment uptake per 6 months 0.80 Beta, n = 100, r = 80 Assumption 
Size of household 2.82 Table distribution, see Table 4 below ONS and assumptions 
Each household contact infected with CHB 0.05 Beta, n = 1000, r = 50 Assumption 
    
Initial distributions    
Acute infection 0.08 Beta, n = 2697, r = 214 HPA 
% of those with CHB who had normal ALT and HBV RNA levels 0.8 Beta, n = 10024, r = 8068 HPA, personal communication 
% of those with raised ALT or HBV RNA levels that were HBeAg+ 0.57 Beta, n = 1956, r = 1108 HPA, personal communication 
    
6 monthly transition probabilities    
HBeAg seroconverted to HCC 0.00005 Beta, α = 0.9187, β = 18373 Shepherd 
5
 
Cleared acute infection - Dirichlet α(199.995,0,0,0,0,0,0.005,0,0) Shepherd 
5
 and assumptions 
HBeAg seroconverted - Dirichlet α(2.01,193.46,3.02,0,1,0,0.5,0,0) Shepherd 
5
 and assumptions 
CHB HBeAg+ (treated) - Dirichlet α(1.76,21.11,171.21,0,5.06,0,0.5,0,0.35) Shepherd 
5
, Woo 
25
 and assumptions 
CHB HBeAg+ (untreated) - Dirichlet α(1.76,9.22,183.12,0,5.06,0,0.5,0,0.35) Shepherd 
5
 and assumptions 
CHB HBeAg- (treated) - Dirichlet α (0.5;96.08;0;97.51;5.06;0;0.5;0;0.35) Shepherd 
5
, Woo 
25
 and assumptions 
CHB HBeAg- (untreated) - Dirichlet α(0.5;14.52;0;179.06;5.06;0;0.5;0;0.35) Shepherd 
5
 and assumptions 
CHB HBeAg+ compensated cirrhosis - Dirichlet α(0;9.2;0;0;178.04;5.06;2.52;0;5.17) Shepherd 
5
 and assumptions 
CHB HBeAg- compensated cirrhosis - Dirichlet α(0;0;0;0;187.25;5.06;2.52;0;5.17) Shepherd 
5
 and assumptions 
Decompensated cirrhosis - Dirichlet α(0;0;0;0;0;150.7;2.52;3.02;43.8) Shepherd 
5
 and assumptions 
Hepatocelluar carcinoma - Dirichlet α(0;0;0;0;0;0;132.7;0;67.34) Shepherd 
5
 and assumptions 
Liver transplant - Dirichlet α(0;0;0;0;0;0;0;177.7;22.24) Shepherd 
5
 and assumptions 
Post Liver transplant to dead - Beta(α = 22.9; β=378.9) Shepherd 
5
 
^PSA, probabilistic sensitivity analysis; *Initial 6 months only; **Annual, converted to 6 monthly in the program; Where Dirichlet distributions are 
specified they represent movements from the named health state to the following, in order: 1) cleared infection, 2) HBeAg seroconverted, 3) CHB 
HBeAg+, 4) CHB HBeAg-, 5) compensated cirrhosis, 6) decompensated cirrhosis, 7) hepatocelluar carcinoma, 8) Liver transplant and 9) dead from 
HBV infection 
 Table 3: Annual utility values and associated parameters used in the HBV model, taken from Shepherd et al 
5
. 
Age group / health state Utility Utility decrement PSA parameters^,** 
0-45 0.91 - - 
46-55 0.85 - - 
56-65 0.8 - - 
66-75 0.78 - - 
    
HBsAg negative - 0 - 
Acute HBV infection - 0 - 
CHB – HBeAg seroconversion - 0 - 
CHB – HBeAg- - 0.04 α=14.7512, β=354.028 
CHB – HBeAg+ - 0.04 α=14.7512, β=354.028 
Compensated cirrhosis - 0.44 α=37.5142, β=47.7543 
Decompensated cirrhosis - 0.54 α=46.4138, β=39.5377 
Hepatocelluar carcinoma - 0.54 α=46.4138, β=39.5377 
Liver transplant (first year) - 0.54 α=46.4138, β=39.5377 
Liver transplant (subsequent years) - 0.32 α=29.0491, β=51.2 
*Note all utility values were divided by 2 in the programming to account for 6 monthly cycles 
^PSA, probabilistic sensitivity analysis 
**All specified as beta distributions 
CHB, chronic hepatitis B 
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Table 4: 6-Monthly costs and associated parameters used in the HBV model, in 2010 UK prices 
Event / health state Mean cost 
(£) 
PSA parameters^ Source 
Intervention cost 20 Gamma (α = (20^2)/(10^2), λ = 20/(10^2)) Assumption 
HBsAg test (laboratory) 10 Gamma, α = (10^2)/(2^2), λ = 10/(2^2) - http://www.uclh.org/aboutus/wwd/Page
s/ProvidertoProviderTariffs.aspx and 
assumptions 
Anti-HBV drug 1,926  BNF 26 
Cost of identifying each 
household contact 
25 Gamma, α = (25^2)/((25/3)^2), λ = 25/((25/3)^2) Assumption 
ALT and ultrasound 69 - 
 
Assumption 
Biopsy 717 - Assumption 
Full viral profile 388 - Assumption 
    
HBsAg negative 0 -  
Acute HBV infection 0 -  
CHB – HBeAg seroconversion 150 Gamma, α = 25.04313, λ = 0.166446 Shepherd 5 
CHB – HBeAg- 303 Gamma, α = 24.74132, λ = 0.081761 Shepherd 5 
CHB – BeAg+ 303 Gamma, α = 24.74132, λ = 0.081761 Shepherd 5 
Compensated cirrhosis 641 Gamma, α = 3538.776, λ = 5.518 Shepherd 5 
Decompensated cirrhosis 5,139 Gamma, α = 1830.328, λ = 0.356148 Shepherd 5 
Hepatocelluar carcinoma 4,580 Gamma, α = 460.012, λ = 0.100447 Shepherd 5 
Liver transplant (first 6 months) 36,788 Gamma, α = 10895.99, λ = 0.296183 Shepherd 5 
Liver transplant (subsequent 
6 months) 
780 Gamma, α = 1295.349, λ = 1.659717 Shepherd 5 
Monitoring cost HBeAg 
seroconverters (annual) 
301 Gamma, α = (301^2)/((301/3)^2), λ = 301/((301/3)^2) Shepherd 5 and 
assumptions 
^PSA, probabilistic sensitivity analysis 
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Table 5: HCV model cost-effectiveness results 
 Total Cost (£)  Total QALYs  ICER (£)* 
Prevalence 2%     
No intervention  244 17.79113  
Intervention  289 17.9539 10,237 
Prevalence 5%    
No intervention  604 17.6025   
Intervention 683 17.6129 7,494 
*ICER, incremental cost-effectiveness ratio 
Results are per person 
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Table 6: HCV cost-effectiveness analysis, sensitivity analysis based on 2% prevalence.  Results are based on one-way 
sensitivity analysis unless otherwise stated 
Parameter ICER (£) 
Base Case 10,273 
£50 per person invited to attend (instead of £20) 17,877 
£75 per person invited to attend (instead of £20) 23,211 
£100 per person invited to attend (instead of £20) 29,904 
80% intervention effect (instead of 17.5%) 6,726 
5% intervention effect (instead of 17.5%) 26,624 
50% initial treatment uptake then 0% thereafter*  20,588 
25% initial treatment uptake then 0% thereafter* 42,005 
Drug cost £10,000 for 6 months (instead of £5,612) 12,763 
Double background testing rate (5.2% instead of 2.6% per year) 11,978 
Utility for SVR health states 95% of base case values 13,809 
QALYs discounted at 1.5% per annum (instead of 3.5%) 6,561 
Costs discounted at 1.5% per annum (instead of 3.5%) 10,345 
Antibody test £30 (instead of £10) 10,993 
Prevalence 1% (instead of 2%) 15,328 
Prevalence 1% (instead of 2%) and £50 per person invited to attend (instead of £20) 29,377 
Time horizon 25 years (instead of lifetime) 17,761 
ICER, incremental cost-effectiveness ratio; SVR, sustained virological response; *individuals 
who do not take up treatment when indicated are assumed to be equivalent to treatment 
failures (i.e non-SVRs) 
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Table 7: HBV model cost-effectiveness results 
 Total Cost (£)  Total QALYs  ICER (£)* 
Prevalence 2%     
No intervention 130,474 18,202.986  
Intervention 176,643 18,205.190 20,907 
Prevalence 20%    
No intervention 1,268,738 17,960.578  
Intervention 1,537,626 17,982.660 12,176 
*ICER, incremental cost-effectiveness ratio 
Results are based on 1,000 PSA runs and index cohorts consisting of 1,000 individuals 
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Table 8: HBV cost-effectiveness analysis, one way sensitivity analysis based on a 2% prevalence 
Parameter ICER (£) 
Base case 20,907 
£50 per person invited to attend for a test (instead of £20) 34,319 
5% intervention effect (instead of 17.5%) 90,048 
No contact tracing 45,933 
Doubling the drug cost (instead of £1,926) 27,101 
No HBeAg seroconversions on initial test / ALT and HBV RNA both low (instead of 80%) 12,773 
Doubled background rate of testing 21,558 
6 household contacts (instead of a mean of 2.82) 17,712 
1% prevalence 30,608 
Time horizon 25 years (instead of lifetime)  71,320 
ICER, incremental cost-effectiveness ratio 
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12 Figures 
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Figure 1: Hepatitis B model schematic 
36 
 
 
Figure 2: Hepatitis C model schematic 
 
All health states are associated with a probability of death.  Other subdivisions include whether or 
not an individuals infection is known, and whether  or not they are receiving treating. 
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Figure 3: Cost-effectiveness acceptability frontier for the HCV model for a 2% prevalence 
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Figure 4: Cost-effectiveness acceptability frontier for the HCV model for a 5% prevalence 
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Figure 5: Cost-effectiveness acceptability frontier for the HCV model for a 2% prevalence assuming that 25% of people 
start treatment as soon as indicated, with the remaining 75% never starting treatment 
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Figure 6: HCV model analysis of covariance (ANCOVA) results for incremental costs and QALYs assuming a 2% prevalence 
level 
 
CC, compenstated cirrhosis; HCC, Hepatocelluar carcinoma; SVR, sustained 
virological response 
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Figure 7: Cost-effectiveness acceptability frontier for the HBV model for a 2% prevalence 
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